[Sisa Today, Reporter Haewon Jeon] We go to the hospital because we are, so to speak, 'in pain.' The goal is to identify the cause of 'pain' — the body's distress signal — and receive appropriate treatment. However, chronic pain that follows like a shadow even after recovery from illness endlessly torments patients and plunges them into suffering.
The World Health Organization (WHO) classifies such chronic pain not as a byproduct of illness but as a 'disease' in its own right. In other words, 'pain' is not just a symptom but a condition that requires treatment.
CEO Yongho Kim of RudaCure Inc. (www.rudacure.com), an assistant professor in the Department of Physiology at Gachon University College of Medicine, has dedicated himself to fundamental research on 'pain' that goes beyond conventional pain relief concepts, stepping up to present a new paradigm for Korea's new drug development industry.
The company's diversified business areas include ▲ CRPS (Complex Regional Pain Syndrome) ▲ neuropathic pain ▲ cancer-induced pain ▲ ocular diseases (dry eye disease, macular degeneration), and the company is developing solutions in all these areas.